Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

To see or not to see - what renders prostate cancer visible?

Emberton M.

Nat Rev Urol. 2019 May;16(5):274-275. doi: 10.1038/s41585-019-0167-5. No abstract available.

PMID:
30867581
2.

Prostate cancer diagnosis: the feasibility of needle-based optical coherence tomography.

Muller BG, de Bruin DM, van den Bos W, Brandt MJ, Velu JF, Bus MT, Faber DJ, Savci D, Zondervan PJ, de Reijke TM, Pes PL, de la Rosette J, van Leeuwen TG.

J Med Imaging (Bellingham). 2015 Jul;2(3):037501. doi: 10.1117/1.JMI.2.3.037501. Epub 2015 Jul 9.

3.

Evaluation of Bisphenol A (BPA) Exposures on Prostate Stem Cell Homeostasis and Prostate Cancer Risk in the NCTR-Sprague-Dawley Rat: An NIEHS/FDA CLARITY-BPA Consortium Study.

Prins GS, Hu WY, Xie L, Shi GB, Hu DP, Birch L, Bosland MC.

Environ Health Perspect. 2018 Nov;126(11):117001. doi: 10.1289/EHP3953.

5.

Do impalpable stage T1c prostate cancers visible on ultrasound differ from those not visible?

Ohori M, Kattan MW, Utsunomiya T, Suyama K, Scardino PT, Wheeler TM.

J Urol. 2003 Mar;169(3):964-8.

PMID:
12576823
6.

Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911).

Bolla M, van Poppel H, Tombal B, Vekemans K, Da Pozzo L, de Reijke TM, Verbaeys A, Bosset JF, van Velthoven R, Colombel M, van de Beek C, Verhagen P, van den Bergh A, Sternberg C, Gasser T, van Tienhoven G, Scalliet P, Haustermans K, Collette L; European Organisation for Research and Treatment of Cancer, Radiation Oncology and Genito-Urinary Groups.

Lancet. 2012 Dec 8;380(9858):2018-27. doi: 10.1016/S0140-6736(12)61253-7. Epub 2012 Oct 19.

PMID:
23084481
7.

Prostate cancer detection rate according to lesion visibility using ultrasound and MRI.

Choi MH, Lee YJ, Jung SE, Lee JY, Choi YJ.

Clin Radiol. 2019 Jun;74(6):474-479. doi: 10.1016/j.crad.2019.02.002. Epub 2019 Mar 4.

PMID:
30846191
8.

Radiomics based targeted radiotherapy planning (Rad-TRaP): a computational framework for prostate cancer treatment planning with MRI.

Shiradkar R, Podder TK, Algohary A, Viswanath S, Ellis RJ, Madabhushi A.

Radiat Oncol. 2016 Nov 10;11(1):148.

9.

Prognostic significance of visible lesions on transrectal ultrasound in impalpable prostate cancers: implications for staging.

Augustin H, Graefen M, Palisaar J, Blonski J, Erbersdobler A, Daghofer F, Huland H, Hammerer PG.

J Clin Oncol. 2003 Aug 1;21(15):2860-8.

PMID:
12885802
10.

Visibility of MRI prostate lesions on B-mode transrectal ultrasound.

Steinkohl F, Luger AK, Pichler R, Bektic J, Rehder P, Lebovici A, Aigner F.

Med Ultrason. 2018 Dec 8;20(4):441-445. doi: 10.11152/mu-1602.

11.

Low-risk prostate cancer patients without visible tumor (T1c) on multiparametric MRI could qualify for active surveillance candidate even if they did not meet inclusion criteria of active surveillance protocol.

Lee DH, Koo KC, Lee SH, Rha KH, Choi YD, Hong SJ, Chung BH.

Jpn J Clin Oncol. 2013 May;43(5):553-8. doi: 10.1093/jjco/hyt041. Epub 2013 Apr 11.

PMID:
23580758
12.

First fully automated planning solution for robotic radiosurgery - comparison with automatically planned volumetric arc therapy for prostate cancer.

Rossi L, Sharfo AW, Aluwini S, Dirkx M, Breedveld S, Heijmen B.

Acta Oncol. 2018 Nov;57(11):1490-1498. doi: 10.1080/0284186X.2018.1479068. Epub 2018 Jul 2.

PMID:
29966472
13.

Volumetric-modulated arc stereotactic body radiotherapy for prostate cancer: dosimetric impact of an increased near-maximum target dose and of a rectal spacer.

Ruggieri R, Naccarato S, Stavrev P, Stavreva N, Fersino S, Giaj Levra N, Mazzola R, Mancosu P, Scorsetti M, Alongi F.

Br J Radiol. 2015 Oct;88(1054):20140736. doi: 10.1259/bjr.20140736. Epub 2015 Aug 3.

14.

Genomic Evaluation of Multiparametric Magnetic Resonance Imaging-visible and -nonvisible Lesions in Clinically Localised Prostate Cancer.

Parry MA, Srivastava S, Ali A, Cannistraci A, Antonello J, Barros-Silva JD, Ubertini V, Ramani V, Lau M, Shanks J, Nonaka D, Oliveira P, Hambrock T, Leong HS, Dhomen N, Miller C, Brady G, Dive C, Clarke NW, Marais R, Baena E.

Eur Urol Oncol. 2019 Feb;2(1):1-11. doi: 10.1016/j.euo.2018.08.005. Epub 2018 Sep 5.

15.
16.

Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95.

Wiegel T, Bottke D, Steiner U, Siegmann A, Golz R, Störkel S, Willich N, Semjonow A, Souchon R, Stöckle M, Rübe C, Weissbach L, Althaus P, Rebmann U, Kälble T, Feldmann HJ, Wirth M, Hinke A, Hinkelbein W, Miller K.

J Clin Oncol. 2009 Jun 20;27(18):2924-30. doi: 10.1200/JCO.2008.18.9563. Epub 2009 May 11.

PMID:
19433689
17.

Cultivating Critical Hope: The Too Often Forgotten Dimension of Critical Leadership Development.

Bishundat D, Phillip DV, Gore W.

New Dir Stud Leadersh. 2018 Sep;2018(159):91-102. doi: 10.1002/yd.20300.

PMID:
29864236
18.
19.

Does prior transurethral resection of prostate compromise brachytherapy quality: a dosimetric analysis.

Cesaretti JA, Stone NN, Stock RG.

Int J Radiat Oncol Biol Phys. 2004 Oct 1;60(2):648-53.

PMID:
15380602
20.

Quantitative bone scan lesion area as an early surrogate outcome measure indicative of overall survival in metastatic prostate cancer.

Brown MS, Kim GHJ, Chu GH, Ramakrishna B, Allen-Auerbach M, Fischer CP, Levine B, Gupta PK, Schiepers CW, Goldin JG.

J Med Imaging (Bellingham). 2018 Jan;5(1):011017. doi: 10.1117/1.JMI.5.1.011017. Epub 2018 Jan 11.

Supplemental Content

Support Center